← Eichor
Study identifier: NCT06963684 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Glaucoma Laser Assessment of Stability and Sustainability

Condition: Glaucoma  ·  Sponsor: Twin Cities Eye Consultants

PhaseNA
Planned participants48
Who can joinAll sexes, 40 Years to no upper limit
Healthy volunteersNo

About this study

The GLASS Study is designed to help researchers learn whether repeating a non-invasive laser treatment called DSLT (Direct Selective Laser Trabeculoplasty) can better control eye pressure in patients with early-stage glaucoma or ocular hypertension. All participants will receive the laser treatment in both eyes. After three months, one eye will be randomly selected to receive a second treatment, while the other eye will serve as a comparison. The goal is to see whether two treatments work better than one at keeping eye pressure low without using daily eye drops. This study will help doctors decide the best way to use this laser treatment to manage glaucoma and delay the need for medication. Participants will be followed for one year to monitor safety, eye pressure, and the need for any additional treatments.

This description comes directly from the study's public registry record.

Talk to the study team

Hannah Schoenecker  ·  612-999-2020  ·  research@tcecmn.com

Always discuss trial participation with your own doctor first.

Locations (1)

Twin Cities Eye ConsultantsCoon Rapids, Minnesota, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06963684